https://www.reuters.com/world/us/cdc-heart-inflammation-cases-ages-16-24-higher-than-expected-after-mrna-covid-19-2021-06-10/ Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions. Read more Skip to main content * World * Business * Markets * Breakingviews * More Sign In Menu June 10, 20216:34 PM UTC United States Heart inflammation in young men higher than expected after Pfizer, Moderna vaccines -U.S. CDC Michael ErmanManojna Maddipatla * * * * 4 minute read A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/ Tami Chappell/File Photo A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/ Tami Chappell/File Photo A higher-than-expected number of young men have experienced heart inflammation after their second dose of the mRNA COVID-19 shots from Pfizer/BioNTech and Moderna, according to data from two vaccine safety monitoring systems, the U.S. Centers for Disease Control and Prevention (CDC) said on Thursday. The CDC and other health regulators have been investigating heart inflammation cases after Israel's Health Ministry reported that it had found a likely link to the condition in young men who received Pfizer's (PFE.N) COVID-19 vaccine. read more The agency said it is still assessing the risk from the condition and has not yet concluded that there was a causal relationship between the vaccines and cases of myocarditis or pericarditis. While some patients required hospitalization, most have fully recovered from their symptoms, the CDC said. More than half of the cases reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) after people had received their second dose of either the Pfizer/BioNTech or Moderna (MRNA.O) vaccines were in people between the ages of 12 and 24, the CDC said. Those age groups accounted for less than 9% of doses administered. "We clearly have an imbalance there," Dr. Tom Shimabukuro, deputy director of the CDC's Immunization Safety Office, said in a presentation to an advisory committee to the U.S. Food and Drug Administration meeting on Thursday. The overwhelming majority of the cases have occurred within a week of vaccination, Shimabukuro said. There were 283 observed cases of heart inflammation after the second vaccine dose in those aged 16 to 24 in the VAERS data. That compares with expectations of 10-to-102 cases for that age range based on U.S. population background incidence rates, the CDC said. Shimabukuro said there was a predominance of males in younger age groups among the reported heart inflammation cases. The median age of patients who experienced the inflammation after a second vaccine dose was 24, according to the VAERS data. Just under 80% of the cases were in men. Shimabukuro also said the Vaccine Safety Datalink (VSD) - another safety monitoring system - showed an increased incidence of heart inflammation in 16 to 39 year olds after their second shot when compared to the rate observed after the first dose. Pfizer said it supports the CDC's assessment of the heart inflammation cases, noting that "the number of reports is small given the number of doses administered." About 130 million people in the United States have received both doses of one of the mRNA vaccines. "It is important to understand that a careful assessment of the reports is ongoing and it has not been concluded that the mRNA COVID-19 vaccines cause myocarditis or pericarditis," the company said in a statement. Moderna said it also has not established a causal association with the condition and its vaccine. It said it is actively working with public health and regulatory authorities to further assess the issue. The CDC said it will hold a meeting of its Advisory Committee on Immunization Practices next week to further evaluate the evidence and assess the risk of myocarditis following mRNA vaccination for COVID-19. Our Standards: The Thomson Reuters Trust Principles. More from Reuters Sign up for our newsletter Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox. Sign up United States United States * 9:14 PM UTCFBI director suggests 'serious charges' coming in probe of Capitol attack FBI Director Chris Wray on Thursday suggested "serious charges" are still coming in the criminal investigation of the deadly Jan. 6 attack on the U.S. Capitol by supporters of former President Donald Trump. United StatesStudy faults California for building homes in wildfire areas10:17 PM UTC United StatesCDC says U.S. travelers can avoid wearing masks in outdoor transit hubs, ferries10:40 PM UTC United StatesU.S. Senate panel unveils $78 billion surface transportation bill9:33 PM UTC United StatesCalifornia appeals judge's ruling striking down assault weapons ban9:25 PM UTC Browse * World * Business * Markets * Breakingviews * Technology * Investigations * Lifestyle About Reuters * About Reuters * Careers * Reuters News Agency * Brand Attribution Guidelines * Reuters Leadership * Reuters Fact Check * Reuters Diversity Report Stay Informed * Download the App * Newsletters Information you can trust Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. Follow Us * * * * * Thomson Reuters Products * Westlaw Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. * Onesource The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs. * Checkpoint The industry leader for online information for tax, accounting and finance professionals. Refinitiv Products * Eikon Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface. * Refinitiv Data Platform Access to real-time, reference, and non-real time data in the cloud to power your enterprise. * World-Check Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. * Advertise With Us * Advertising Guidelines * Cookies * Terms of Use * Privacy * Corrections * Site Feedback All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. (c) 2021 Reuters. All rights reserved